Institution
Ochsner Medical Center
Healthcare•New Orleans, Louisiana, United States•
About: Ochsner Medical Center is a healthcare organization based out in New Orleans, Louisiana, United States. It is known for research contribution in the topics: Population & Medicine. The organization has 980 authors who have published 1159 publications receiving 49961 citations. The organization is also known as: Ochsner Hospital & Ochsner Foundation Hospital.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: A heart team approach with appropriate patient selection, careful assessment of LM lesions, and meticulous procedural technique makes PCI a valid alternative to CABG for ULM stenosis.
Abstract: This article reviews the latest data on unprotected left main (ULM) percutaneous coronary intervention (PCI) versus coronary artery bypass graft (CABG) surgery, with a focus on the NOBLE and EXCEL trials. In EXCEL trial, the primary endpoint at 3 years was 15.4% in the PCI group and 14.7% in the CABG group (p = 0.02 for non-inferiority of PCI versus CABG). In NOBLE, the primary endpoint at 5 years was 28% and 18% for PCI and CABG, respectively (HR 1.51, CI 1.13–2.0, which did not meet the criteria for non-inferiority of PCI to CABG; p for superiority of CABG was 0.0044). Higher repeat revascularization and non-procedural myocardial infarction were noted in PCI group but there was no difference in all-cause or cardiac mortality between the two groups. A heart team approach with appropriate patient selection, careful assessment of LM lesions, and meticulous procedural technique makes PCI a valid alternative to CABG for ULM stenosis.
2 citations
••
TL;DR: Tests from the interventional arena evaluating new agents in the treatment of myocardial infarction, comparing with coronary artery bypass grafting surgery in patients with diabetes, and reporting registry data on long-term treatment with dual antiplatelet therapy are explored.
Abstract: This article provides information and commentary on recent clinical trials related to primary prevention in cardiovascular diseases including lipids, hypertension, and diabetes. It also focuses on novel therapeutic advances in heart failure with devices and therapeutic agents. In addition, we explore trials looking at the effects of the investigational agents azimilide and dronedarone in the treatment of arrhythmias, application of established therapies/devices to larger populations, and the impact of hypercoagulability and aortic arch plaques on the incidence of stroke. Finally, we conclude with trials from the interventional arena evaluating new agents in the treatment of myocardial infarction, comparing percutaneous coronary intervention with coronary artery bypass grafting surgery in patients with diabetes, and reporting registry data on long-term treatment with dual antiplatelet therapy. Some of the preliminary data presented are from unpublished reports and may be subject to change in the final publications.
2 citations
•
TL;DR: Key national treatment goals, guidelines, and algorithms for T2DM management are summarized in a way that clarifies their similarities and areas of disparity, for use by managed care organizations and other healthcare professionals.
Abstract: Diabetes affects an estimated 25.8 million US adults, or 8.3% of the population. By 2050, the prevalence of type 2 diabetes mellitus (T2DM) in the United States may be as high as 1 in 3 adults. This paper summarizes key national treatment goals, guidelines, and algorithms for T2DM management in a way that clarifies their similarities and areas of disparity, for use by managed care organizations and other healthcare professionals. In addition, the role of long-standing and newer classes of antihyperglycemic agents, including incretin-related agents, bromocriptine, and colesevelam, will be reviewed, as will emerging research on the role of lifestyle intervention in T2DM and prediabetes. Lastly, comparative and long-term clinical efficacy data on incretin therapy, reported at the American Diabetes Association's 2011 71st Scientific Sessions, will be summarized. Although the treatment landscape for T2DM has increased substantially in complexity, major guidelines have similar goals. While established, relatively inexpensive, and thoroughly investigated antihyperglycemic agents maintain popularity, incretin-based agents offer glycemic efficacy along with other benefits relative to weight loss or neutrality and low rates of hypoglycemia. In addition, the feasibility of matching patients to appropriate lifestyle intervention, for both diabetes and diabetes prevention, is increasing.
2 citations
••
TL;DR: Surgical excision is curative in teratomas of the head and neck in infants and children and sonographic procedures may be useful in differentiation of cystic, solid, or mixed tumors.
Abstract: Teratomas of the head and neck in infants and children, though uncommon, should be included in the differential diagnosis of head and neck masses in this age group. Roentgenographic examinations should be an integral part of the initial evaluation. Characteristic tooth-like calcifications are often present within teratomas. Sonographic procedures may be useful in differentiation of cystic, solid, or mixed tumors. Computerized tomography may be recommended to evaluate the extent of the lesion and to assess intracranial involvement. As in the case we have presented, surgical excision is curative. Complications of surgery have been due to hemorrhage and/or respiratory difficulties.
2 citations
••
2 citations
Authors
Showing all 993 results
Name | H-index | Papers | Citations |
---|---|---|---|
Carl J. Lavie | 106 | 1135 | 49318 |
Michael R. Jaff | 82 | 442 | 28891 |
Michael F. O'Rourke | 81 | 451 | 35355 |
Mandeep R. Mehra | 80 | 644 | 31939 |
Richard V. Milani | 80 | 454 | 23410 |
Christopher J. White | 77 | 621 | 25767 |
Bruce A. Reitz | 74 | 333 | 18457 |
Robert C. Bourge | 69 | 273 | 24397 |
Sana M. Al-Khatib | 69 | 377 | 17370 |
Hector O. Ventura | 66 | 478 | 16379 |
Andrew Mason | 63 | 360 | 15198 |
Aaron S. Dumont | 60 | 386 | 13020 |
Philip J. Kadowitz | 55 | 379 | 11951 |
David W. Dunn | 54 | 195 | 8999 |
Lydia A. Bazzano | 51 | 267 | 13581 |